Intratumoral immunotherapy is gaining momentum, but its applicability (and likely efficacy too) is limited by the need for repeated injections because of limited intratumoral persistence of the injected drugs. We utilized plasmid interleukin-12 DNA (pIL-12 or tavokinogene telseplasmid; 'tavo') and in vivo intratumoral electroporation (i.t.-tavo-EP) to acheive prolonged intratumoral IL-12 expression in 15 patients with Merkel cell carcinoma (MCC), an aggressive, immunogenic cancer. Systemic delivery of IL-12, a cytokine that facilitates T-helper-1 responses, had previously been associated with severe adverse events (AEs), including death. I.t.-tavo-EP administered on days 1, 5, and 8 resulted in sustained (day 22) intratumoral IL-12 expression without any systemic or severe AEs. Resultant local inflammation led to systemic immune responses, with regression of non-injected MCC lesions in 3 of 10 (30%) patients and an overall response rate of 25% (3/12) in patients with metastatic MCC. Gene electrotransfer, specifically i.t.-tavo-EP, warrants further investigation for immunotherapy of cancer. Research. on December 3, Structured Abstract Purpose: Interleukin-12 (IL-12) promotes adaptive type-1 immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AEs), including death. This pilot trial investigated safety, efficacy, and immunologic activity of intratumoral delivery of IL-12 plasmid DNA (tavo) via in vivo electroporation (i.t.-tavo-EP) in patients with Merkel cell carcinoma (MCC), an aggressive virus-associated skin cancer. Experimental Design: Fifteen MCC patients with superficial injectable tumor(s) received i.t.tavo-EP on days 1, 5, and 8 of each cycle. Patients with locoregional MCC (Cohort A, N=3) received one cycle before definitive surgery in week 4. Patients with metastatic MCC (Cohort B, N=12) received up to 4 cycles total, administered at least six weeks apart. Serial tumor and blood samples were collected. Results: All patients successfully completed at least one cycle with transient, mild (Grade 1, 2) AEs and without significant systemic toxicity. Sustained (day 22) intratumoral expression of IL-12 protein was observed along with local inflammation and increased tumor-specific CD8 + T cell infiltration, which led to systemic immunologic and clinical responses. The overall response rate was 25% (3/12) in Cohort B, with two patients experiencing durable clinical benefit (16 and 55+ months respectively). Two Cohort A patients (one with pathologic complete remission) were recurrence-free at 44+ and 75+ months. Conclusions: I.t.-tavo-EP was safe and feasible without systemic toxicity. Sustained local expression of IL-12 protein and local inflammation led to systemic immune responses and clinically meaningful benefit in some patients. Gene electrotransfer, specifically i.t.-tavo-EP, warrants further investigation for immunotherapy of cancer. Research. on December 3,
Introduction
Prior to the success of immune checkpoint inhibitors, immunomodulatory cytokines were the backbone of cancer immunotherapy for decades and provided proof-of-concept for successfully harnessing the immune system against cancer. Interleukin-2 (IL-2) and interferon (IFN) are approved by the United States Food and Drug Administration for advanced melanoma and renal cell carcinoma. Therapeutic utility of cytokines, however, has been limited by low response rates, significant treatment-associated systemic toxicities, and the paucity of predictive biomarkers. The pursuit of novel cytokines with better efficacy and of novel approaches to deliver cytokines without systemic toxicity remain areas of active investigation in cancer immunotherapy, both as monotherapy and in combination immunotherapy regimens.
IL-12 is a 70 kD heterodimeric, multifunctional protein discovered in 1989 and rapidly recognized as a master regulator of adaptive type 1 cell-mediated immunity (1, 2) . IL-12 production by innate immune cells (e.g. monocytes, macrophages, neutrophils, and dendritic cells) polarizes naïve CD4 + T-cells towards the T-helper-1 (T H 1) phenotype; these cells then produce high levels of IFN-γ upon restimulation (3) (4) (5) . IL-12 also induces the production of IFN-γ and increased proliferation and cytotoxicity of natural killer cells and CD8 + T-cells (6, 7) .
Additionally, IL-12 up-regulates the expression of human leukocyte antigen (HLA) class I and II, and intercellular adhesion molecule-1 on human cancer cells (melanoma), enhancing T cell extravasation and increasing antigen binding (8) . These unique biological properties and promising preclinical data prompted active investigation of recombinant IL-12 (rIL-12) in the treatment of advanced solid tumors and hematologic malignancies. In early phase clinical trials using systemic administration of rIL-12, encouraging biological and clinical responses were observed, but were tempered by severe multi-organ toxicities that included dose-limiting Research.
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Author Manuscript Published OnlineFirst on October 3, 2019; DOI: 10.1158/1078-0432.CCR- cytopenias, hepatitis, and even treatment-related deaths in two patients (9) (10) (11) . These observations led to development of localized IL-12 delivery directly to the tumor in forms other than recombinant protein. This was attempted through direct injection of IL-12 plasmid; viral vectors; or modified fibroblasts, autologous tumor cells, or dendritic cells engineered to secrete IL-12 (12) (13) (14) (15) (16) (17) (18) (19) . These methods showed efficacy in preclinical models, but not as much in clinical trials, likely related to low gene transfer efficiency (20) . In 2008, Daud et al reported a clinical trial using intratumoral injection of IL-12 plasmid DNA (tavo) followed by in vivo electroporation (i.t.-tavo-EP) to enhance the efficiency of transfection and thus local IL-12 protein expression in 24 patients with advanced melanoma (21) . Treatment led to robust doseproportional expression of IL-12 protein within injected lesions (21) MCC is a rare, highly aggressive skin cancer associated with the Merkel cell polyomavirus (MCPyV) and ultraviolet radiation exposure. MCC is considered immunogenic, with reports of spontaneous regression and responsiveness to immunotherapy (22-27). Strong CD8 + T cell infiltration is associated with dramatically improved survival, independent of stage at presentation (28) . The mechanisms of this immunogenicity, however, have only recently been understood (27 given day was capped at 2 mL or 1.0 mg. The plasmid injection in each zone was followed immediately by electroporation before moving onto the next zone. For electroporation, the applicator was inserted into the same zone in which the plasmid was injected, and six electrical pulses at a field strength (E+) 1300 volts/cm and pulse width of 100 μs at 400 msec intervals were administered as described (21) .
Clinical assessments
Clinical endpoints included safety and tolerability, as well as efficacy, which measured both injected and non-injected lesion regression, recurrence-free survival in Cohort A, and objective response by RECIST v1.1 in Cohort B. AEs were graded according to National Cancer Institute indicated. After completion of treatment, patients were followed at least annually for relapse, disease progression, and overall survival.
Biopsy and peripheral blood collection
Serial tumor biopsies and peripheral blood samples were collected from all patients to evaluate cellular immunologic changes, as well as changes in IL-12 p70 protein expression in treated tumors (Supplemental Fig. 1 ). Pre-treatment tumor biopsy was attempted on day 1 and posttreatment biopsy of the same tumors on day 22; the latter was substituted by surgical specimen collection during week 4 in Cohort A patients. Tumor samples were divided for biomarker studies: 1) formaldehyde-fixed paraffin embedded (FFPE) blocks for immunohistochemistry (IHC), multi-spectral IHC or gene expression, 2) flash-frozen for protein expression, and 3) processed immediately for isolation and culture of tumor-infiltrating lymphocytes (TIL) as previously described (33) . Blood samples for immune response analysis were collected at baseline, day 22, and week 6 of each cycle. Peripheral blood mononuclear cells (PBMCs) were isolated using routine Ficoll gradient centrifugation and were immediately cryopreserved.
Immune response analyses
Tumor-MCPyV status was assessed using T-antigen IHC (CM2B4 antibody, Santa Cruz Biotechnology) and/or detection of MCPyV oncoprotein antibodies (AMERK test; Table 1 ) as previously described (34-36).
Immunohistochemistry analyses
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Author Manuscript Published OnlineFirst on October 3, 2019; DOI: 10.1158/1078-0432.CCR- Standard histology was performed on all biopsies. Monochromatic IHC staining with antibodies to CK20 (KS20.8, Dako), CD8 (C8/144B, Dako), CD4 (SP35, Cell Marque), CM2B4 (MCPyV T-antigen, sc-136172, Santa Cruz), MHC class I (EMR8-5, MBL), PD-L1 (E1L3N, Cell Signaling), and FoxP3 (14-5773-82, eBioscience) was performed. H&E and IHC-stained slides were reviewed for evidence of tumor and necrosis prior to performing further biomarker analyses. For multispectral IHC staining, FFPE specimens were deparaffinized and rehydrated, subjected to heat-induced antigen retrieval, and stained as described previously (37) . Staining was performed using the following antibodies: PD-1 (EPR4877, AbCam), PD-L1 (SP142, Spring Bio), CD4 (RBT-CD4, BioSB), CD8 (C8/144B, Dako), and CD68 (PG-M1; Dako). Slides were imaged with a Vectra Automated Quantitative Pathology Imaging System (Perkin Elmer).
Images were analyzed using inForm Software (Perkin Elmer) and were evaluated by a pathologist.
IL-12 p70 protein expression
To determine whether i.t.-tavo-EP led to increased expression of the IL-12 protein in the TME, pre-and post-biopsies were collected, lysed, and analyzed for IL-12 p70 protein, a heterodimer comprised of p40 and p35 subunits. Pre-and post-treatment frozen paired biopsies were weighed before homogenization in lysis buffer, lysed, and subjected to centrifugation to sediment insoluble cellular material prior to determination of IL-12 p70 protein levels using a multianalyte immunoassay platform (MAGPIX  , Luminex Detection beads were then added to the plates before quantifying the analyte. For analysis, replicate values below the lower limit of quantification (LLOQ) were adjusted to the run-specific LLOQ value. All values were then adjusted to pg/g of sample and averaged to produce an average expression value. No replicate values were adjusted or excluded from analysis on the basis of the upper limit of quantification.
Gene expression analysis
FFPE-extracted RNA (approximately 50 ng) was analyzed using the human Immunology V2 panel and the nCounter  platform (NanoString  Technologies, LabCorp, Seattle, WA). This panel profiles 594 immunology-related human genes as well as two types of built-in controls: positive controls (spiked RNA at various concentrations to evaluate the overall assay performance) and 15 negative controls (to normalize for differences in total RNA input). Total RNA was isolated using the AllPrep kit (Qiagen, Valencia, CA) from FFPE specimens after histologic confirmation of evaluable tumor. Sample preparation and hybridization was carried out according to the manufacturer's instructions. In brief, 5 µL (100 ng) of total RNA was hybridized at 96°C overnight and then digitally analyzed for frequency of each RNA species.
Data were collected using the nCounter  Digital Analyzer, and data normalization and analysis were carried out using the nSolver™ software (V.3). Normalization factors were derived from the geometric mean of housekeeping genes, mean of negative controls, and geometric mean of positive controls.
RNA extraction (tissue pellets):
Research. Tumor tissue samples procured by punch biopsy or fine needle aspirate (FNA) were homogenized in phosphate-buffered saline without Ca 2+ or Mg 2+ (Life Technologies, Carlsbad, CA) with protease inhibitors (cComplete-mini, EDTA-free; Roche Life Science, Indianapolis, ID). Clarified supernatants and cell pellets were stored separately at -80°C. Total RNA was isolated from cell pellets using TRIzol ® Reagent (Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's protocol. Total RNA concentrations were determined using the NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific) and quality was assessed using the 2100 Bioanalyzer (Agilent, Santa Clara, CA) for both the standard and smear analyses by LabCorp (Seattle, WA). Samples were excluded from analysis if Bioanalyzer RIN score was less than 2.0 and smear analysis indicated <30% of RNA were less than 300 bp. Center) or B37/KEWWRSGGFSF-PE tetramer (Buus Lab, Denmark) as described (33, (38) (39) (40) . 
MCPyV-specific tetramer staining

T cell receptor sequencing
Total genomic DNA was extracted from whole flash-frozen tumor biopsies using the spin column method and the DNeasy kit (Qiagen). High-throughput deep sequencing was used to determine T cell receptor beta locus (TRB) complementarity-determining region 3 (CDR3) with the Illumina Genome Analyzer (Adaptive Biotechnologies, Seattle, WA) using the immunoSEQ immune-profiling system (41) . Read normalization was performed as described (42) .
Identification of the Vβ, Dβ, and Jβ gene segments contributing to each TCRβ CDR3 sequence was performed using the published algorithm (41) . The T cell fraction within MCC tumors was determined by calculating the percentage of a tumor sample that was composed of T cells. To determine whether there was a change in T cell enrichment between pre-and post-treatment specimens, the fold change in the T cell fraction was calculated as the difference between the post-treatment T cell fraction and pre-treatment T cell fraction over the pre-treatment T cell fraction.
Statistical analyses
Descriptive statistics were used to summarize baseline patient characteristics, safety, clinical response, and immunological response variables. All injected and non-injected tumors were assessed and responses to treatment were classified as complete responses (CR), partial responses (PR), stable disease (SD), or progressive disease (PD) per RECIST v1.1 definitions (32) . The overall objective response rate (ORR) per standard RECIST v1.1 guidelines is also reported for those patients with distant metastases in Cohort B. Progression-free survival and overall-survival were calculated from the day of treatment initiation to documented disease progression and/or death, respectively. All analyses and summaries were produced using SAS ® version 9.3 (or higher).
Results:
Patient Characteristics
Fifteen patients (Pt) with locoregional (Cohort A, n=3) or metastatic (Cohort B, n=12) MCC were enrolled between January 2012 and January 2015; their baseline characteristics are summarized in therapy, 40% had received prior systemic chemotherapy, and 40% had received prior biologic therapy with none receiving prior PD-1/PD-L1 blockade ( Table 1) the last i.t.-tavo-EP treatment; this was diagnosed upon elective resection of a pre-existing liver lesion that had been presumed to be an MCC metastasis at the time of study entry.
Clinical outcomes
Treatment and clinical outcomes are summarized in Table 3 . In Cohort A, two of three patients continue to be recurrence-free at 75+ months (Pt#6) and 44+ months (Pt#16) from treatment initiation; the third patient (Pt#9) had disease recurrence at 9 months. Pt#16, who had biopsy- 
Intratumoral IL-12 gene and protein expression
Elevated intratumoral IL-12 gene and protein expression were observed in post-treatment specimens (Figures 1A and 1B) . Specifically, increased expression (by 2-fold or more) of IL-12 p70 protein was observed post-treatment (on day 22) versus baseline (day 1) in 6 out of 10 (60%) patients with evaluable paired tumor biopsies ( Figure 1B) . While we did not measure systemic IL-12 levels in the peripheral blood in this study, there was no evidence of clinically-significant systemic spillage of IL-12 beyond the local TME, based on a complete lack of systemic TRAEs in this study and similar to results reported by Daud et al in the Phase 1 study (21) .
Increased peripheral and intratumoral MCPyV-specific T cells are associated with response
Using our library of MCPyV-specific HLA class-I tetramers (33, (38) (39) (40) , we tracked MCPyVspecific T cell responses, both locally in the treated lesions (Figure 2A) , and also systemically, in the peripheral blood ( Figure 2B ) and in untreated lesions (Figure 3A,B) . Thirteen of 15 patients expressed suitable HLA class-I alleles for tetramer screening (Supplemental Table 1 ).
We performed MCPyV-specific tetramer staining on paired pre-and post-therapy TIL from five patients with MCC-VP tumors (Figure 2A) can increase intratumoral T cells, including those specific for MCPyV epitopes, but that additional mechanisms of local immune evasion may limit clinical responses. associated with increased expression of PD-1 and PD-L1 within the TME (Fig 3D) . Notably, IL-12 has been shown to significantly induce expression of IFN-, which can drive potent antitumor effects via enhanced immunogenicity and direct tumoral-static mechanisms, but this cytokine can also trigger upregulation of PD-L1 and IDO-1 in the TME (45) . The majority (6 of 10; 60%) had greater than 2-fold increase in IL-12 protein levels suggesting sustained expression (at day 22) after treatment on days 1, 5, and 8. Negative control is an HLA mismatched donor. C: T cell receptor (TCR) beta chain sequencing was used to determine TCR variable beta chain diversity using ImmunoSeq V3 (Adaptive Biotechnology) from pre-and post-treatment tumor specimens (patient number is shown on X axis, and * denotes patients in which the pre and post-treatment samples were from different lesions). Data are presented as fold change (a ratio of the difference between the post-treatment T cell fraction and pre-treatment T cell fraction over the pretreatment T cell fraction). Bars are colored in correlation with clinical response, responder (R, green) and non-responder (NR, red). The dotted line denotes a greater than or equal to 2-fold change. D & E: Multispectral immunohistochemistry images of pre-treatment (D) show an MCC tumor (CK20, white/light blue) with very few infiltrating T cells (CD8 in green and CD4 in red). Three weeks after treatment (E), there is a large infiltrate of CD8 T cells (green), accompanied by increased PD-1 (magenta) and PD-L1 (orange) and loss of tumor (CK20, white/light blue). Abbreviations: RT: Radiation therapy; C1: Cycle 1; C2: Cycle 2 ; Tx: treatment
Discussion
